Plasma extracellular vesicle messenger RNA profiling identifies prognostic EV signature for non-invasive risk stratification for survival prediction of patients with pancreatic ductal adenocarcinoma.
Extracellular vesicles
Pancreatic ductal adenocarcinoma
Plasma extracellular vesicle
Prognosis
mRNA biomarkers
Journal
Journal of hematology & oncology
ISSN: 1756-8722
Titre abrégé: J Hematol Oncol
Pays: England
ID NLM: 101468937
Informations de publication
Date de publication:
03 02 2023
03 02 2023
Historique:
received:
15
09
2022
accepted:
23
01
2023
entrez:
4
2
2023
pubmed:
5
2
2023
medline:
8
2
2023
Statut:
epublish
Résumé
The prognosis of pancreatic ductal adenocarcinoma (PDAC) is one of the most dismal of all cancers and the median survival of PDAC patients is only 6-8 months after diagnosis. While decades of research effort have been focused on early diagnosis and understanding of molecular mechanisms, few clinically useful markers have been universally applied. To improve the treatment and management of PDAC, it is equally relevant to identify prognostic factors for optimal therapeutic decision-making and patient survival. Compelling evidence have suggested the potential use of extracellular vesicles (EVs) as non-invasive biomarkers for PDAC. The aim of this study was thus to identify non-invasive plasma-based EV biomarkers for the prediction of PDAC patient survival after surgery. Plasma EVs were isolated from a total of 258 PDAC patients divided into three independent cohorts (discovery, training and validation). RNA sequencing was first employed to identify differentially-expressed EV mRNA candidates from the discovery cohort (n = 65) by DESeq2 tool. The candidates were tested in a training cohort (n = 91) by digital droplet polymerase chain reaction (ddPCR). Cox regression models and Kaplan-Meier analyses were used to build an EV signature which was subsequently validated on a multicenter cohort (n = 83) by ddPCR. Transcriptomic profiling of plasma EVs revealed differentially-expressed mRNAs between long-term and short-term PDAC survivors, which led to 10 of the top-ranked candidate EV mRNAs being tested on an independent training cohort with ddPCR. The results of ddPCR enabled an establishment of a novel prognostic EV mRNA signature consisting of PPP1R12A, SCN7A and SGCD for risk stratification of PDAC patients. Based on the EV mRNA signature, PDAC patients with high risk displayed reduced overall survival (OS) rates compared to those with low risk in the training cohort (p = 0.014), which was successfully validated on another independent cohort (p = 0.024). Interestingly, the combination of our signature and tumour stage yielded a superior prognostic performance (p = 0.008) over the signature (p = 0.022) or tumour stage (p = 0.016) alone. It is noteworthy that the EV mRNA signature was demonstrated to be an independent unfavourable predictor for PDAC prognosis. This study provides a novel and non-invasive prognostic EV mRNA signature for risk stratification and survival prediction of PDAC patients.
Sections du résumé
BACKGROUND
The prognosis of pancreatic ductal adenocarcinoma (PDAC) is one of the most dismal of all cancers and the median survival of PDAC patients is only 6-8 months after diagnosis. While decades of research effort have been focused on early diagnosis and understanding of molecular mechanisms, few clinically useful markers have been universally applied. To improve the treatment and management of PDAC, it is equally relevant to identify prognostic factors for optimal therapeutic decision-making and patient survival. Compelling evidence have suggested the potential use of extracellular vesicles (EVs) as non-invasive biomarkers for PDAC. The aim of this study was thus to identify non-invasive plasma-based EV biomarkers for the prediction of PDAC patient survival after surgery.
METHODS
Plasma EVs were isolated from a total of 258 PDAC patients divided into three independent cohorts (discovery, training and validation). RNA sequencing was first employed to identify differentially-expressed EV mRNA candidates from the discovery cohort (n = 65) by DESeq2 tool. The candidates were tested in a training cohort (n = 91) by digital droplet polymerase chain reaction (ddPCR). Cox regression models and Kaplan-Meier analyses were used to build an EV signature which was subsequently validated on a multicenter cohort (n = 83) by ddPCR.
RESULTS
Transcriptomic profiling of plasma EVs revealed differentially-expressed mRNAs between long-term and short-term PDAC survivors, which led to 10 of the top-ranked candidate EV mRNAs being tested on an independent training cohort with ddPCR. The results of ddPCR enabled an establishment of a novel prognostic EV mRNA signature consisting of PPP1R12A, SCN7A and SGCD for risk stratification of PDAC patients. Based on the EV mRNA signature, PDAC patients with high risk displayed reduced overall survival (OS) rates compared to those with low risk in the training cohort (p = 0.014), which was successfully validated on another independent cohort (p = 0.024). Interestingly, the combination of our signature and tumour stage yielded a superior prognostic performance (p = 0.008) over the signature (p = 0.022) or tumour stage (p = 0.016) alone. It is noteworthy that the EV mRNA signature was demonstrated to be an independent unfavourable predictor for PDAC prognosis.
CONCLUSION
This study provides a novel and non-invasive prognostic EV mRNA signature for risk stratification and survival prediction of PDAC patients.
Identifiants
pubmed: 36737824
doi: 10.1186/s13045-023-01404-w
pii: 10.1186/s13045-023-01404-w
pmc: PMC9896775
doi:
Substances chimiques
RNA, Messenger
0
Biomarkers, Tumor
0
Types de publication
Multicenter Study
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
7Informations de copyright
© 2023. The Author(s).
Références
Curr Mol Med. 2013 Mar;13(3):340-51
pubmed: 23331006
Cancer Discov. 2017 Aug;7(8):818-831
pubmed: 28572459
J Natl Cancer Inst. 2018 Aug 1;110(8):803-811
pubmed: 29873743
Int J Cancer. 2015 Jun 1;136(11):2616-27
pubmed: 25388097
J Hepatobiliary Pancreat Sci. 2019 Feb;26(2):63-72
pubmed: 30561106
Ann Oncol. 2017 Apr 1;28(4):741-747
pubmed: 28104621
Gut. 2020 Mar;69(3):540-550
pubmed: 31562239
Nat Med. 2011 Apr;17(4):500-3
pubmed: 21460848
J Extracell Vesicles. 2018 Nov 23;7(1):1535750
pubmed: 30637094
Cytoskeleton (Hoboken). 2010 Sep;67(9):545-54
pubmed: 20803696
Biochim Biophys Acta Mol Cell Res. 2019 Jan;1866(1):2-15
pubmed: 30076859
Biochem Biophys Res Commun. 2008 Apr 25;369(1):149-56
pubmed: 18155661
J Extracell Vesicles. 2018 Dec 28;8(1):1560809
pubmed: 30651940
Mol Cancer. 2021 Jul 17;20(1):95
pubmed: 34273975
World J Oncol. 2019 Feb;10(1):10-27
pubmed: 30834048
Cancer Immunol Res. 2016 Mar;4(3):225-33
pubmed: 26842750
Cells. 2020 Feb 05;9(2):
pubmed: 32033496
Nanoscale. 2018 Jan 18;10(3):881-906
pubmed: 29265147
Exp Cell Res. 2005 Apr 1;304(2):506-17
pubmed: 15748895
Nature. 2015 Feb 26;518(7540):495-501
pubmed: 25719666
Gastroenterology. 2021 Mar;160(4):1330-1344.e11
pubmed: 33212097
Cancers (Basel). 2020 Jan 13;12(1):
pubmed: 31941049
Int J Mol Sci. 2019 Jul 05;20(13):
pubmed: 31284422
Cell. 2019 Apr 4;177(2):428-445.e18
pubmed: 30951670
Ann Oncol. 2012 Jul;23(7):1713-22
pubmed: 22241899
PLoS Med. 2010 Jul 13;7(7):e1000307
pubmed: 20644708
J Immunol. 2013 Sep 15;191(6):2956-66
pubmed: 23956427
Ann Transl Med. 2019 Nov;7(22):645
pubmed: 31930046
Channels (Austin). 2012 Sep-Oct;6(5):352-61
pubmed: 22992466
J Gastrointest Oncol. 2012 Jun;3(2):105-19
pubmed: 22811878
J Extracell Vesicles. 2018 Jun 04;7(1):1481321
pubmed: 29887978
J Hepatobiliary Pancreat Sci. 2018 Feb;25(2):155-161
pubmed: 29130611
Proc Natl Acad Sci U S A. 2005 Oct 25;102(43):15545-50
pubmed: 16199517
Sci Rep. 2020 Jan 23;10(1):1039
pubmed: 31974468
Curr Opin Genet Dev. 2002 Jun;12(3):349-61
pubmed: 12076680
Lancet. 2011 Aug 13;378(9791):607-20
pubmed: 21620466
Mol Biol Evol. 2011 Jan;28(1):859-71
pubmed: 20924084
Caspian J Intern Med. 2013 Spring;4(2):627-35
pubmed: 24009950
Nature. 2015 Jul 9;523(7559):177-82
pubmed: 26106858
Cells. 2020 Aug 25;9(9):
pubmed: 32854228
J Extracell Vesicles. 2018 Dec 18;8(1):1555410
pubmed: 30574280
Cell. 2020 Aug 20;182(4):1044-1061.e18
pubmed: 32795414
Sci Transl Med. 2017 May 24;9(391):
pubmed: 28539469
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
Front Immunol. 2018 Apr 30;9:738
pubmed: 29760691
Mol Cancer. 2020 Mar 2;19(1):50
pubmed: 32122374
Gastroenterology. 2019 Jan;156(1):108-118.e4
pubmed: 30240661